{'fraction_non_alphanumeric': 0.04072043852779953, 'fraction_numerical': 0.01957713390759593, 'mean_word_length': 5.4873096446700504, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Five-year clinical follow-up after sirolimus-eluting stent implantation for the treatment of coronary in-stent restenosis

BackgroundLate vessel failure by restenosis or thrombosis is a potential limitation of drug-eluting stent implantation. MethodsWe conducted a prospective 5-year clinical evaluation following implantation of sirolimus-eluting Cypher stents for in-stent restenosis regardless of the patient's symptomatic status. A complete 5-year follow-up is reported for 192 consecutive patients. ResultsThe cumulative rate of death was 5.2%, of cardiac death was 4.2%, of nonfatal myocardial infarction was 4.2%, of definite stent thrombosis was 1.0%, of probable stent thrombosis was 1.0%, of possible stent thrombosis was 2.1%, of target lesion revascularization was 9.4%, of target vessel revascularization was 13.5%, and of major adverse cardiovascular events (death of all causes, nonfatal myocardial infarction, and repeat revascularization; major adverse cardiovascular event) was 22.9%, respectively. ConclusionThese results, of a comparably large series, indicate that the implantation of sirolimus-eluting Cypher stents for the treatment of coronary in-stent restenosis is effective and safe and associated with a stable clinical course in the very long term.